Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Interventional Pulmonology Research Program

Our Interventional Pulmonary faculty are actively engaged in several research studies dedicated to advancing our knowledge of the diagnosis and treatment of patients with a variety of airway disorders. Patients seen by the Johns Hopkins Interventional Pulmonary service have the opportunity to participate in studies that investigate novel treatments and therapies for lung cancer, pleural diseases and other respiratory disorders. If any of the listed research studies below sound like they may apply to you, you can learn more by contacting our research office at IPresearch@jhmi.edu or 443-287-3701.

View Clinics

  • Patients with COPD have high nerve activity in the airways of their lungs, leading to narrowed airways. Current treatments only temporarily open the airways. Targeted Lung Denervation Therapy is experimental at this time and involves delivering radiofrequency energy through a catheter in the bronchoscope in order to remove the ability of the nerves located on the outside of the airways to send signals to the brain. The purpose of this study is to evaluate the efficacy of the Nuvaira™ Lung Denervation System, which is intended to treat COPD subjects on optimal medical care in order to reduce moderate or severe exacerbations and related hospitalizations.

    Lead Investigator: Lonny Yarmus, DO
    Sponsor: Nuvaira, Inc.
    Links:  https://www.airflowtrial.com/https://clinicaltrials.gov/ct2/show/NCT03639051

  • Malignant pleural mesothelioma is a tumor of the lining of your lungs. The treatment for malignant pleural mesothelioma may involve the removal of the tumor through surgery, radiotherapy and/or chemotherapy. The purpose of this study is to determine the safety and efficacy of an investigational agent, rAd-IFN, in combination with Celecoxib (a non-steroidal anti-inflammatory drug) and Gemcitabine (a chemotherapy drug) in inhibiting tumor growth in patients with malignant pleural mesothelioma.

    Lead Investigator: David Feller-Kopman, MD
    Sponsor: Trizell Ltd.
    Links:  https://clinicaltrials.gov/ct2/show/NCT03710876

  • The growth of technology has generated an increasing number of procedures available to physicians, such as electromagnetic navigation (EMN) bronchoscopy and EMN percutaneous transthoracic needle aspiration (PTTNA) in the pulmonary field. The purpose of this study is to prospectively characterize the learning curve of interventional pulmonary fellows in achieving competency performing EMN procedures, including EMN-bronchoscopy and EMN-PTTNA. Following each pulmonary procedure, the site fellowship director faculty will complete a validated, procedural assessment electronic form.

    Lead Investigator: Hans Lee, MD
    Coordinating Site: Johns Hopkins Hospital

  • This study is concerned with retrospectively evaluating the patterns of use and efficacy of tPA/Dornase (MIST2) for the treatment of parapneumonic pleural effusions and/or empyema. We aim to retrospectively review the management and clinical outcomes of pleural disease patients that were seen at an inpatient pulmonary service at Johns Hopkins who received tPA/Dornase for empyema.

    Lead Investigator: Lonny Yarmus, DO
    Coordinating Site: University of North Carolina

  • Tunneled pleural catheter placement is an effective method used to manage pleural effusion. Some patients with the tunneled pleural catheter tend to develop a condition called auto-pleurodesis, which is the absence of excess fluid returning, while others do not. The purpose of this study is to identify a way to predict the type of patients who develop auto-pleurodesis status post insertion of tunneled pleural catheters.
    Lead Investigator: Lonny Yarmus, DO
    Sponsor: Rocket Medical, plc
    Linkshttps://clinicaltrials.gov/ct2/show/NCT02092155https://ichgcp.net/clinical-trials-registry/NCT02092155

  • Blood based biomarker panels can be used to detect genetic mutations or epigenetic alterations that correlate to lung cancer. This can improve early detection of lung cancer or help rule out lung cancer for patients with incidental nodules. The purpose of this study is to obtain whole blood specimens that can be used in identifying new biomarkers for neoplasms of the lung, and to use this data towards future cancer-related test development.
    Lead Investigator: Lonny Yarmus, DO
    Sponsor: Exact Sciences Corporation
    Linkshttps://clinicaltrials.gov/ct2/show/NCT03633006

  • EGFR tyrosine kinase receptors (EGFR-TKIs) are used as an effective, targeted therapy for patients with advanced non-small cell lung cancer (NSCLC). Identification of EGFR mutations is considered an independent predictor of TKI response and survival in NSCLC patients with targeted therapy matched to the molecular status of the tumors. The preferred sample type for this assessment is tissue but retrieval and analysis of tissue have multiple limitations. Thus, the evaluation of plasma is an alternate and viable method to identify EGFR mutations. The purpose of this study is to validate plasma circulating tumor DNA (ctDNA) EGFR analysis as an alternative method to tissue analysis in patients with stage IV NSCLC.
    Lead Investigator: David Feller-Kopman, MD
    Sponsor: Sysmex Inostics, Inc.
    Links: https://www.sysmex-inostics.com/

  • Vacuum drainage and gravity drainage are two commonly used drainage methods practiced by patients who receive indwelling tunneled pleural catheters. There is no current evidence suggesting whether one method is better than the other in regards to pain or other discomforts during the drainage process. The purpose of this study is to compare the positive and negative effects of these two type of drainages.
    Lead Investigator: Lonny Yarmus, DO
    Sponsor: Rocket Medical
    Linkshttp://usa.rocketmedical.com/

  • Diagnosing a lung nodule can take 3-4 hospital visits and procedures when the initial tests are inconclusive. The purpose of this study is to combine separate procedures that would normally be done in separate sessions at different times. The study aims to determine the impact of using existing FDA approved technologies during one visit to diagnose the lung nodule and the impact it has on patient care factors.
    Lead Investigator: Lonny Yarmus, DO
    Sponsor: Veran Medical Technologies, Inc.
    Linkshttps://clinicaltrials.gov/ct2/show/NCT03338049?term=NCT03338049&rank=1

  • Percepta is a new test used to analyze bronchial epithelial cells via genomic analysis to determine the risk for lung cancer in patients who have undergone bronchoscopies that found no malignancies and have a prior history of smoking. Results from this test can help determine whether a patient may be considered for CT surveillance instead of invasive procedures. This study serves as an observational registry study that collects data on the use of Percepta test to support the possible outcomes of the test. The registry enrolls patients for whom the Percepta test has been clinically indicated.
    Lead Investigator: Hans Lee, MD
    Sponsor: Veracyte, Inc.
    Linkshttps://www.veracyte.com/our-products/percepta

 
back to top button